Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans

Teneligliptin, a dipeptidyl peptidase-4 inhibitor, is used to treat type 2 diabetes mellitus. FMO3 and CYP3A4 metabolize teneligliptin into teneligliptin sulfoxide. This study examined the effects of FMO3 (rs909530, rs1800822, rs2266780, and rs2266782) and CYP3A4 (rs2242480) polymorphisms on tenelig...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jin-Woo, Kim, Kyoung-Ah, Kim, Jong-Min, Park, In-Hwan, Park, Ji-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426351/
https://www.ncbi.nlm.nih.gov/pubmed/34512362
http://dx.doi.org/10.3389/fphar.2021.736317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426351/
https://www.ncbi.nlm.nih.gov/pubmed/34512362
http://dx.doi.org/10.3389/fphar.2021.736317

Ejemplares similares